T A B L E O F C O N T E N T S A B S T R A C T

Background
While most guidelines recommend the use of insulin in women whose pregnancies are affected by pre-existing diabetes, oral agents have obvious benefits for patient acceptability and adherence. It is necessary, however, to assess the effects of these anti-diabetic agents on maternal and infant health outcomes. Additionally, women with previous gestational diabetes mellitus are increasingly found to be predisposed to impaired glucose tolerance and, despite the potential need for intervention for these women, there has been little evidence about the use of oral anti-diabetic agents by these women pre-conceptionally or during a subsequent pregnancy.
Objectives
To investigate the effect of oral anti-diabetic agents in women with pre-existing diabetes mellitus, impaired glucose tolerance or previous gestational diabetes planning a pregnancy or pregnant women with diabetes mellitus on maternal and infant health.
The use of oral antidiabetic agents for management of gestational diabetes in a current pregnancy is evaluated in a separate Cochrane review.
Search strategy
We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (March 2010) .
Selection criteria
We included randomised and quasi-randomised trials.
Data collection and analysis
Two review authors independently assessed trial eligibility for inclusion.
Main results
We identified 13 trials published as 25 papers using the Cochrane Pregnancy and Childbirth group literature search, and an additional ongoing trial. We have not included any trials in the review. One trial is awaiting assessment and we have excluded twelve trials because they evaluated treatment of women with gestational diabetes or women with polycystic ovary syndrome, were not randomised controlled trials or data were not available.
Authors' conclusions
Little randomised evidence is available evaluating the use of oral anti-diabetic agents in women with diabetes mellitus, impaired glucose tolerance, previous gestational diabetes mellitus planning a pregnancy or pregnant women with pre-existing diabetes mellitus. Large trials comparing any combination of oral anti-diabetic agent, insulin and dietary and lifestyle advice in these women, reporting on maternal and infant health outcomes, glycaemic control, women's views on the intervention and long-term health outcomes for mother and child, are required to guide clinical practice.
P L A I N L A N G U A G E S U M M A R Y
Oral anti-diabetic agents for women with pre-existing diabetes mellitus, impaired glucose tolerance or previous gestational diabetes mellitus
Pregnant women with type 1 or type 2 diabetes are at a greater risk of adverse outcomes in pregnancy, such as miscarriage or large babies and preterm birth. Being pregnant can trigger diabetes in women with impaired glucose tolerance or can accelerate the development of diabetic complications in women who are already diabetic. Women who have gestational diabetes are at risk of developing diabetes later in life. This means that management is important for women with diabetes and also for women with impaired glucose tolerance or previously diagnosed gestational diabetes.
It is usually recommended that women with diabetes have good control of their blood sugar levels before they become pregnant, and guidelines suggest insulin be used where additional control is required. Women with type 1 diabetes are likely to have used insulin for some time. Women with type 2 diabetes may have good control of their diabetes with diet and lifestyle changes alone, or with the use of an oral anti-diabetic agent. Women with diabetes using an oral anti-diabetic agent are usually advised to change to insulin before pregnancy for better blood sugar control and because there is little known about the effects of oral anti-diabetic agents in early pregnancy. Oral agents are, however, more convenient and acceptable than insulin injections and do not require the intensive education that is needed with insulin injections.
This review sought to investigate the effect of oral anti-diabetic agents in women with pre-existing diabetes mellitus, impaired glucose tolerance, or previous gestational diabetes, or women with diabetes mellitus planning a pregnancy on maternal and infant health.
We were not able to include any of the studies identified by the Cochrane literature search in the review. One trial has not been published in full yet and is awaiting assessment. An additional trial is ongoing. Further research is required comparing the effects of the oral antidiabetic agents with insulin and dietary and lifestyle advice in these women, in order to determine effects on the health of the mother and her baby, the level of blood sugar control achieved, women's views on the treatment, and long-term outcomes for the woman and child.
B A C K G R O U N D
Pre-existing diabetes mellitus in pregnancy
Pre-existing, or pre-gestational diabetes includes pregnant women who have been previously diagnosed with type 1 or type 2 diabetes or, in rare cases, other forms of diabetes mellitus. While some parts of the world have a significantly greater prevalence of diabetes than others, globally it is estimated that the prevalence of diabetes for adults aged 20-79 years in 2010 was 6.6%; this is projected to reach 7.8% by 2030, with 7.9% of adults having impaired glucose tolerance in 2010 (projected to increase to 8.4% by 2030) a total of 900 million people in both groups combined by 2030 (IDF 2009) . It is predicted that approximately one in three people with diabetes are undiagnosed (Cowie 2006) . In pregnancy, the prevalence of pre-existing diabetes is reported as being up to 1.3% and is increasing (Bell 2008; Lawrence 2008) . In particular, the rate of type 2 diabetes in pregnancy is rising faster than that of type 1 diabetes in pregnancy (Bell 2008; Lawrence 2008) . These trends are further modified by maternal age and ethnicity, with a higher prevalence of pre-existing diabetes with increasing maternal age (Lawrence 2008). In addition to the impact of diabetes on health, pre-existing diabetes in pregnancy is commonly associated with a number of adverse health outcomes for both the woman and child. In pregnant women, pre-existing diabetes has been associated with caesarean section, hypertension in pregnancy and preterm birth (Langer 2000; Ray 2001; Walkinshaw 2005) . Pregnancy in women with pre-existing diabetes may also exacerbate the effects of diabetes on renal function and retinopathy (Leguizamon 2007; Sheth 2002) . Pre-existing diabetes in pregnancy is associated with an increased risk of fetal congenital anomaly and spontaneous abortion (Kitzmiller 1996) . Fetal hyperinsulinaemia associated with pre-gestational diabetes affects infants by increasing the incidence of macrosomia (birthweight greater than 4000 g), large-for-gestational age (birthweight greater than 90th centile for age), shoulder dystocia, neonatal hypoglycaemia, preterm birth, hyperbilirubinaemia, hypocalcaemia and neonatal intensive care admission (Jensen 2004; Macintosh 2006; Ray 2001; Walkinshaw 2005; Weintrob 1996 ). Furthermore, long-term follow up of infants of diabetic mothers suggests that exposure to maternal diabetes in utero increases the risk of obesity and type 2 diabetes for these children in the future (Dabelea 2000).
Management of pre-existing diabetes mellitus before and during pregnancy
Adverse outcome in women with pre-existing diabetes and their infants is related to the level of glycaemic control achieved during pregnancy. Therefore, in pre-conception and antenatal care there is a strong focus on the management of maternal glucose concentrations. Prior to conception, it is recommended that women with diabetes receive multidisciplinary care including an assessment of diabetes complications, advice on glycaemic control, diet, the importance of family planning, maternal diabetes complications and fetal risks (ADIPS 2005; Meltzer 2003; NICE 2008) . Continuation of this care and additional monitoring of fetal growth are recommended for the duration of pregnancy (NICE 2008) . Oral anti-diabetic agents are more commonly used by those with type 2 diabetes than those with type 1 diabetes, who will not achieve adequate glycaemic control on oral anti-diabetics alone. It is currently recommended that oral anti-diabetic agents be substituted with in-sulin therapy in women planning pregnancy and during pregnancy (ADIPS 2005; NICE 2008 ).
Oral anti-diabetic agents and use in pre-existing diabetes
Oral anti-diabetic agents, commonly referred to as oral hypoglycaemic agents or oral anti-hyperglycaemic agents, act in a variety of ways. While widely used in men and women suffering type 2 diabetes, their use in women planning a pregnancy or during pregnancy has been controversial, with conflicting reports on the safety of these agents in pregnancy. Because of concerns over the safety of oral agents, insulin is the preferred agent for glycaemic management in women with pre-existing diabetes in pregnancy (ADA 2004; ADIPS 2005; Kitzmiller 2008; Meltzer 2003) . Current recommendations suggest that women planning or continuing pregnancy use insulin, although oral anti-diabetic agents may be considered on an individual basis since the harm from uncontrolled diabetes may outweigh any potential harm from oral antidiabetic agents. While the lack of safety data in pregnancy of oral anti-diabetic agents has prevented them from being recommended for use during pregnancy, it is also argued that the use of oral anti-diabetic agents alone, including glyburide (glibenclamide) and metformin, may be inadequate to successfully manage the post-prandial glycaemic peaks associated with type 2 diabetes mellitus (Jovanovic 2007). However, oral anti-diabetic agents are convenient, preferable to insulin injections and do not require the intensive education associated with insulin therapy. Where oral agents alone are not sufficient to achieve glycaemic control, they may also be used in combination to reduce the frequency or dose of insulin therapy. A retrospective study of diabetic women in South Africa who remained on oral anti-diabetic agents, transferred from oral agents to insulin and those who transferred from diet alone to insulin reported no difference in fetal anomaly rates (Ekpebegh 2007) . This study did, however, report a significantly higher perinatal mortality rate in those continuing on oral anti-diabetic agents alone than those who were on insulin therapy. Meta-analyses and reviews of observational studies have been unable to provide definitive conclusions on the effects of oral anti-diabetic agents for the treatment of diabetes in pregnancy (Gutzin 2003; Ho 2007) . Common anti-diabetic agents used include sulfonylureas, biguanides, thiazolidinediones, alpha-glucosidase inhibitors, meglitinides and peptide analogues. Biguanides, including metformin, reduce peripheral insulin resistance, inhibit gluconeogenesis and reduce plasma triglyceride concentrations (DeFronzo 1995; Stumvoll 1995; Yogev 2004) . Metformin does cross the placenta and therefore there have been concerns about its use in pregnancy (Hellmuth 2000; Kovo 2007; NICE 2008; Slocum 2002) . The use of metformin for the treatment of gestational diabetes has been evaluated in a randomised controlled trial (Rowan 2008) . This trial found that compared with insulin, metformin was not associated with increased perinatal complications, with a tendency to less severe neonatal hypoglycaemia, with less maternal weight gain and a greater acceptability of metformin treatment. In this study metformin treatment was commenced in the latter half of pregnancy, between 20 and 34 weeks' gestation. Although it has been suggested that metformin increases the odds of pregnancy and prevents pregnancy loss in women with polycystic ovary syndrome (PCOS), there is no definitive evidence on its safety in pregnancies, especially those complicated by pre-existing diabetes (Brock 2005; Ho 2007) . Follow up at age 18 months of 126 infants born to 109 mothers with PCOS who conceived on and continued metformin during pregnancy reported similar size and motor-social development in the metformin exposed infants compared with infants of women not known to have PCOS (Glueck 2004) . Sulfonylureas act to enhance insulin secretion and peripheral tissue sensitivity to insulin while also reducing hepatic clearance of insulin (DeFronzo 1984; Homko 2006; Simonson 1984; Yogev 2004) ; examples include glyburide (glibenclamide) and glimepiride. The main side effect of these agents is hypoglycaemia and while first generation sulfonylureas cross the placenta, it is unclear whether second generation agents, including glyburide (glibenclamide), do and what effect this has on the developing fetus (Jovanovic 2007; Kraemer 2006; Sivan 1995; Slocum 2002) . A major concern is the ability of sulfonylureas to stimulate fetal hyperinsulinaemia (Coetzee 2007). However, a randomised controlled trial of treatment of women with gestational diabetes using glyburide (glibenclamide), a second generation sulfonylurea, or insulin, found that there were no differences in macrosomic or large-for-gestational-age infants between the two groups (Langer 2000). Alpha-glucosidase inhibitors such as acarbose and miglitol reduce postprandial glucose levels by decreasing the breakdown and absorption of carbohydrates in the intestine (Slocum 2002; Yogev 2004) . There has been little evidence of the use of these agents in pregnancy (Ho 2007). Alpha-glucosidase inhibitors are typically used in combination with other oral anti-diabetic agents or insulin (Yogev 2004) . Thiazolidinediones, including rosiglitazone and pioglitazone, result in increased insulin sensitivity and decreased lipid availability (Slocum 2002; Yogev 2004) . There is little evidence on the use of thiazolidinediones in pregnancy (Ho 2007). However, placental transfer of thiazolidinediones has been reported (Chan 2005). Furthermore, caution has been placed on the use of rosiglitazone in type 2 diabetics due to an increased risk of adverse cardiovascular outcomes (Nissen 2007). Meglitinides act by increasing pancreatic insulin secretion. There is little evidence of their use in pregnancy (Slocum 2002) . Similarly, we could find no evidence on the use of peptide analogues such as incretin mimetics and dipeptidyl peptidase-4 inhibitors in pregnancy.
Previous gestational diabetes and management before and during pregnancy
Gestational diabetes mellitus (GDM) is 'carbohydrate intolerance resulting in hyperglycaemia of variable severity with onset or first recognition during pregnancy' (WHO 1999) . GDM affects approximately 7% of all pregnancies and is associated with an increased risk of a number of adverse perinatal outcomes including macrosomia, shoulder dystocia, perineal trauma, pre-eclampsia (hypertension in pregnancy), and neonatal hypoglycaemia. Although gestational diabetes resolves in 90% of cases, women with a history of gestational diabetes represent a unique group of women who are at significant risk for developing recurrent GDM and for later development of type 2 diabetes mellitus (Kim 2002; Kim 2007) . A history of GDM has also been associated with insulin resistance and impaired insulin secretion (Damm 1995; Seghieri 2007) . Despite the potential need for intervention for these women, there is little evidence on the use of oral agents pre-conceptionally or during pregnancy. The most appropriate form of treatment for gestational diabetes in a current pregnancy is unclear. The Cochrane review 'Treatment of gestational diabetes' (Alwan 2009) compares treatment options for women with GDM, including the use of oral anti-diabetic agents such as metformin and glyburide (glibenclamide). It found that while women with GDM should be considered for treatment, it is unclear which treatment option should be offered. Recently, the results of the Metformin in Gestational diabetes trial suggests that the use of metformin compared with insulin is not associated with increased perinatal complications (Rowan 2008) . Although 46.30% of women in the metformin arm required supplemental insulin, women preferred metformin to insulin treatment. Follow up of these women and their children is ongoing.
Rationale for review
With the increasing prevalence of type 1, type 2 and gestational diabetes, there is an increasing need for evidence-based management of women with pre-existing diabetes or a history of gestational diabetes pre-conceptionally and during pregnancy. While most guidelines recommend the use of insulin in place of oral anti-diabetic agents, oral agents have obvious benefits for patient acceptability and adherence. Furthermore, there is little evidence on the efficacy of these agents on maternal and infant health. It is therefore necessary to assess the benefits and harms of anti-diabetic agents in women with pre-existing diabetes planning pregnancy and during pregnancy. The use of oral antidiabetic agents for management of gestational diabetes in a current pregnancy is evaluated in the Cochrane review 'Treatment of gestational diabetes' (Alwan 2009).
O B J E C T I V E S
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised and quasi-randomised controlled trials.
Types of participants
Women with diabetes mellitus, impaired glucose tolerance or previous gestational diabetes mellitus planning a pregnancy or pregnant women with diabetes mellitus.
Types of interventions
1. Oral anti-diabetic versus no medication 2. Oral anti-diabetic versus another oral anti-diabetic 3. Oral anti-diabetic versus insulin 4. Oral anti-diabetic versus insulin + oral anti-diabetic 5. Oral anti-diabetic + insulin versus insulin 6. Different regimens of any of the above 4. weekly current awareness alerts for a further 44 journals plus monthly BioMed Central email alerts. Details of the search strategies for CENTRAL and MEDLINE, the list of handsearched journals and conference proceedings, and the list of journals reviewed via the current awareness service can be found in the 'Specialized Register' section within the editorial information about the Cochrane Pregnancy and Childbirth Group. Trials identified through the searching activities described above are each assigned to a review topic (or topics). The Trials Search Co-ordinator searches the register for each review using the topic list rather than keywords. We did not apply any language restrictions.
Types of outcome measures
Data collection and analysis
Selection of studies
Two review authors independently assessed for inclusion all the potential studies we identified as a result of the search strategy. We resolved any disagreement through discussion or, if required, we consulted a third author.
Data extraction and management
We designed a form to extract data. We identified no eligible studies. For eligible studies, at least two review authors would have extracted the data using the agreed form. We would have resolved discrepancies through discussion or, if required, we would have consulted a third author. We would have entered data into Review Manager software (RevMan 2008) and checked for accuracy. When information regarding any of the above was unclear, we would have attempted to contact authors of the original reports to provide further details.
Assessment of risk of bias in included studies
We planned for two review authors to independently assess risk of bias for each included study using the criteria outlined in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2009). We would have resolved any disagreement by discussion or by involving a third assessor.
(1) Sequence generation (checking for possible selection bias)
We planned to describe for each included study the method used to generate the allocation sequence in sufficient detail to allow an assessment of whether it should produce comparable groups. We planned to assess the method as:
• adequate (any truly random process, e.g. random number table; computer random number generator),
• inadequate (any non-random process, e.g. odd or even date of birth; hospital or clinic record number) or,
• unclear.
(2) Allocation concealment (checking for possible selection bias)
We planned to describe for each included study the method used to conceal the allocation sequence and determine whether intervention allocation could have been foreseen in advance of, or during recruitment, or changed after assignment. We planned to assess the methods as:
• adequate (e.g. telephone or central randomisation; consecutively numbered sealed opaque envelopes);
• inadequate (open random allocation; unsealed or nonopaque envelopes, alternation; date of birth);
(3) Blinding (checking for possible performance bias)
We planed to describe for each included study the methods used, if any, to blind study participants and personnel from knowledge of which intervention a participant received. We would consider that studies were at low risk of bias if they were blinded, or if we judged that the lack of blinding could not have affected the results. We would assess blinding separately for different outcomes or classes of outcomes. We planned to assess the methods as:
• adequate, inadequate or unclear for participants; • adequate, inadequate or unclear for personnel; • adequate, inadequate or unclear for outcome assessors.
(4) Incomplete outcome data (checking for possible attrition bias through withdrawals, dropouts, protocol deviations)
We planned to describe for each included study, and for each outcome or class of outcomes, the completeness of data including attrition and exclusions from the analysis. We planned to state whether attrition and exclusions were reported, the numbers included in the analysis at each stage (compared with the total randomised participants), reasons for attrition or exclusion where reported, and whether missing data were balanced across groups or were related to outcomes. Where sufficient information is reported, or can be supplied by the trial authors, we will re-include missing data in the analyses which we undertake in future updates. We planned to assess methods as:
• adequate; • inadequate; • unclear.
(5) Selective reporting bias
We planned to describe for each included study how we investigated the possibility of selective outcome reporting bias and what we found. We planned to assess the methods as:
• adequate (where it is clear that all of the study's prespecified outcomes and all expected outcomes of interest to the review have been reported);
• inadequate (where not all the study's pre-specified outcomes have been reported; one or more reported primary outcomes were not pre-specified; outcomes of interest are reported incompletely and so cannot be used; study fails to include results of a key outcome that would have been expected to have been reported);
(6) Other sources of bias
We planned to describe for each included study any important concerns we have about other possible sources of bias. We planned to assess whether each study was free of other problems that could put it at risk of bias:
• yes; • no; • unclear.
(7) Overall risk of bias
We planned to make explicit judgements about whether studies are at high risk of bias, according to the criteria given in the Handbook (Higgins 2009). With reference to (1) to (6) above, we planned to assess the likely magnitude and direction of the bias and whether we considered it likely to impact on the findings. We would have explored the impact of the level of bias through undertaking sensitivity analyses.
Measures of treatment effect
Dichotomous data
For dichotomous data, we planned to present results as summary risk ratio with 95% confidence intervals.
Continuous data
For continuous data, we planned to use the mean difference if outcomes were measured in the same way between trials. We planned to use the standardised mean difference to combine trials that measure the same outcome, but use different methods.
Unit of analysis issues
Cluster-randomised trials
We planned to include cluster-randomised trials in the analyses along with individually randomised trials. We planned to adjust their sample sizes using the methods described in Gates 2005 using an estimate of the intracluster correlation co-efficient (ICC) derived from the trial (if possible), or from another source. If ICCs from other sources had been used, we planned to report this and conduct sensitivity analyses to investigate the effect of variation in the ICC. If we identified both cluster-randomised trials and individually-randomised trials, we planned to synthesise the relevant information. We will consider it reasonable to combine the results from both if there is little heterogeneity between the study designs and the interaction between the effect of intervention and the choice of randomisation unit is considered to be unlikely. We would also have acknowledged heterogeneity in the randomisation unit and performed a separate meta-analysis.
Crossover trials
We planned to exclude crossover trials from this review.
Dealing with missing data
For included studies, we planned to note levels of attrition. The impact of including studies with high levels of missing data in the overall assessment of treatment effect would have been explored by using sensitivity analysis. For all outcomes, we planned to carry out analyses, as far as possible, on an intention-to-treat basis, i.e. we planned to attempt to include all participants randomised to each group in the analyses. The denominator for each outcome in each trial would be the number randomised minus any participants whose outcomes are known to be missing. Where we were unable to extract data from publications of trials, we planned to contact author(s) or site, seeking clarification or data as required. We would acknowledge the efforts of these authors in the review.
Assessment of heterogeneity
We planned to assess statistical heterogeneity in each meta-analysis using the T 2 , I 2 and Chi 2 statistics. We would regard heterogeneity as substantial if I 2 is greater than 30% and either T 2 is greater than zero, or there is a low P-value (less than 0.10) in the Chi 2 test for heterogeneity.
Assessment of reporting biases
If there were 10 or more studies in the meta-analysis we would investigate reporting biases (such as publication bias) using funnel plots. We would assess funnel plot asymmetry visually, and use formal tests for funnel plot asymmetry. For continuous outcomes we would use the test proposed by Egger 1997, and for dichotomous outcomes we would use the test proposed by Harbord 2006. If we detect asymmetry in any of these tests or by a visual assessment, we would perform exploratory analyses to investigate it.
Data synthesis
We planned to carry out statistical analysis using the Review Manager software (RevMan 2008) . We planned to use random-effects meta-analysis for combining data from trials.
Subgroup analysis and investigation of heterogeneity
We planned to carry out the following subgroup analyses:
1. type of diabetes (type I diabetes mellitus, type II diabetes mellitus, impaired glucose tolerance, previous gestational diabetes mellitus); 2. polycystic ovary syndrome (present or not); 3. glycaemic control (glycaemic targets achieved or not; e.g. pre-conception, 1st trimester, 2nd trimester, 3rd trimester). We planned to use primary outcomes in subgroup analysis. For fixed-effect meta-analyses we planned to conduct planned subgroup analyses classifying whole trials by interaction tests as described by Deeks 2001. For random-effects meta-analyses, we planned to assess differences between subgroups by inspection of the subgroups' confidence intervals; non-overlapping confidence intervals indicate a statistically significant difference in treatment effect between the subgroups.
Sensitivity analysis
We planned to carry out sensitivity analysis on primary outcomes to explore the effect of trial quality assessed by allocation concealment and other risk of bias components, by omitting studies rated as inadequate for these components. If we had included clusterrandomised or quasi-randomised trials, we planned to perform sensitivity analysis.
Results of the search
A total of 26 trials were identified. The Cochrane Pregnancy and Childbirth group literature search identified 13 trials published as 25 papers to be considered for inclusion, and we identified one ongoing trial. We included no trials in the review, and excluded 12 trials. One trial (Hutchinson 2008) is awaiting assessment and one trial is ongoing (Hague 2010). Hutchinson 2008 compares a combination of glyburide and metformin with insulin for glycaemic control in women with pre-existing type 2 diabetes mellitus or gestational diabetes mellitus not previously requiring insulin. We are awaiting full publication of this trial for inclusion in the review. Hague 2010 is a randomised controlled trial comparing, in women with a history of gestational diabetes, the use of extended release metformin with placebo on maternal and infant health outcomes.
Included studies
No trials identified by the literature search were eligible for inclusion.
Excluded studies
Of the studies excluded from the review, seven trials evaluated treatment of women with gestational diabetes mellitus in this pregnancy (Anjalakshi 2007; Bertini 2005; Golladay 2006 (Tang 2010) evaluates the use of insulin sensitising agents to improve reproductive outcomes and metabolic parameters for women with PCOS and menstrual disturbance.
Risk of bias in included studies
Effects of interventions
D I S C U S S I O N
The increasing prevalence and effects of pre-existing diabetes mellitus on maternal and infant health outcome highlight the importance of evaluating evidence-based management for these women both pre-conceptionally and during pregnancy. Additionally, women with impaired glucose tolerance or gestational diabetes in a previous pregnancy represent a group of women with relative insulin resistance, and are at risk of developing type 2 diabetes mellitus. Appropriate management of these women is unclear.
There were no data from randomised controlled trials evaluating the use of oral anti-diabetic agents for women with pre-existing diabetes mellitus, impaired glucose tolerance or previous gestational diabetes pre-conceptionally or for pregnant women with pre-existing diabetes that was able to be included in this review.
One trial published in 1971 (Notelovitz 1971) randomised women with gestational diabetes or type 2 diabetes mellitus to receive tolbutamide, chlorpropamide, insulin or diet alone. Although the study reported some maternal and infant health outcomes, data from women with type 2 diabetes and those with gestational diabetes were unable to be separated by the study site, and this precluded its inclusion in the review. Notelovitz and colleagues suggested, from the combined data, that the oral antidiabetic agents provided good glycaemic control without increases in perinatal mortality and congenital abnormality. Given that the data were unable to be separated, these results from the trial could not be applied to women in this review.
Despite the limited evidence of the efficacy and safety of oral antidiabetic agents for women included in this review, the greater acceptability and potential compliance with oral antidiabetic agents suggest that further evidence is required. Large, high-quality randomised controlled trials evaluating the effects of oral anti-diabetic agents in women with pre-existing diabetes mellitus, impaired glucose tolerance or previous gestational diabetes mellitus planning pregnancy and pregnant women with pre-existing diabetes mellitus should include an assessment of maternal and infant health outcome, the adequacy of glycaemic control, women's views on the intervention and their health status and long-term health outcomes for mother and child. The combination of interventions will vary with type of diabetes or glucose intolerance, including comparisons between oral anti-diabetic agents, insulin therapy and dietary and lifestyle management.
One trial awaiting classification (Hutchinson 2008) randomised women with gestational diabetes or type 2 diabetes to insulin or a combination of glyburide and metformin and collected outcome data on maternal glycaemic control and maternal and infant health outcome. An additional trial is ongoing (Hague 2010), comparing metformin and placebo in women with a history of gestational diabetes and maternal and infant health outcome.
A U T H O R S ' C O N C L U S I O N S
Implications for practice
Little evidence is available evaluating the use of oral anti-diabetic agents in women with diabetes mellitus, impaired glucose tolerance or previous gestational diabetes mellitus planning a pregnancy or pregnant women with pre-existing diabetes mellitus. Current guidelines recommend the use of insulin in women with pre-existing diabetes mellitus, with the use of oral anti-diabetic agents considered on an individual basis.
Implications for research
Large, randomised controlled trials evaluating the use of oral antidiabetic agents in women with diabetes mellitus, impaired glucose tolerance or previous gestational diabetes mellitus planning a pregnancy or pregnant women with pre-existing diabetes mellitus. In particular, trials should compare oral antidiabetics with insulin or dietary and lifestyle control, and compare different oral antidiabetic agents. Outcomes reported should include maternal and infant health outcome, glycaemic control parameters, women's views on the intervention and long-term health outcomes for mother and child.
A C K N O W L E D G E M E N T S
As part of the pre-publication editorial process, this review has been commented on by two peers (an editor and referee who is external to the editorial team), a member of the Pregnancy and Childbirth Group's international panel of consumers and the Group's Statistical Adviser.
